Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens

Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens

Abstract Low success rates during drug development are due, in part, to the difficulty of defining drug mechanism‐of‐action and molecular markers of therapeutic activity. Here, we integrated 199,219 drug sensitivity measurements for 397 unique anti‐cancer drugs with genome‐wide CRISPR loss‐of‐functi...

Full description

Bibliographic Details
Main Authors: Emanuel Gonçalves, Aldo Segura‐Cabrera, Clare Pacini, Gabriele Picco, Fiona M Behan, Patricia Jaaks, Elizabeth A Coker, Donny van derMeer, Andrew Barthorpe, Howard Lightfoot, Tatiana Mironenko, Alexandra Beck, Laura Richardson, Wanjuan Yang, Ermira Lleshi, James Hall, Charlotte Tolley, Caitlin Hall, Iman Mali, Frances Thomas, James Morris, Andrew R Leach, James T Lynch, Ben Sidders, Claire Crafter, Francesco Iorio, Stephen Fawell, Mathew J Garnett
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Molecular Systems Biology
Subjects:
CRISPR‐Cas9
drug mechanism‐of‐action
protein networks
Online Access:https://doi.org/10.15252/msb.20199405

Internet

https://doi.org/10.15252/msb.20199405

Similar Items